Details of the four firms that have been selected to manufacture generic versions of Novartis’s nilotinib treatment for chronic myeloid leukemia have been revealed by the Medicines Patent Pool.
Four firms – India’s Eugia, Hetero and Dr Reddy's, along with Indonesian-based company BrightGene – have been selected by the Medicines Patent Pool to manufacture generic versions of Novartis’s nilotinib treatment for chronic myeloid leukemia as sub-licensees, as part of an MPP licensing deal with the originator.
The quartet of firms will be able to manufacture generic versions of nilotinib in India and seven middle-income countries where...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
